Target Identification & Drug Development

Research Focus

We are currently focused on several disease areas, including but not limited to immuno-oncology (e.g., liver cancer, lung cancer, and gastrointestinal tumors), fibrosis (e.g., liver fibrosis, pulmonary fibrosis, and renal fibrosis), autoimmune diseases (e.g., rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, and systemic lupus erythematosus), and aging-associated changes of the immune system.

Overview

Drug Development

6 warheads and 3 pipeline projects have finished HIT.

Project Code Indication Drug Design HIT Lead Optimization PCC
Warhead CI-01 Solid Cancer
CI-02 Solid Cancer
CI-03 Solid Cancer
CI-05 Solid Cancer
CI-08 Autoimmune Diseases
CI-09 Autoimmune Diseases
Pipeline BP-201 Autoimmune Diseases
BP-101 Solid Cancer
BP-102 Solid Cancer

Target Discovery

cover 10+ oncology or autoimmune diseases, 8 candidate targets entered in-vitro validation stage.

Proj Class Data Preparation Target Recommendation Dry-lab Evaluation In-vitro Validation In-vivo Validation
Tumor-specific targets mining
Autoimmune diseases targets mining
Fibrosis diseases targets mining
Immune cells targets mining

Collaborations

10 +diseases with unmet clinical needs 20 top tier academic hospitals 30 top tier PIs 30 projects 

Representative Projects

Esophageal Cancer

Zhihua LIU, M.D.
  • Top-tier cancer hospital with annual outpatient volume >730k, inpatient volume >53k and surgery volume >18k
  • Director of State Key Laboratory of Molecular Oncology
  • KOL in esophageal cancer

Gastric Cancer

Jiafu JI, M.D.
  • Top-tier cancer hospital with annual outpatient volume >750k, inpatient volume >96k and surgery volume >17k
  • Director of Peking University Cancer Research Center
  • KOL in gastric cancer

Inflammatory Bowel Disease

Huji XU, M.D.
  • Top-tier hospital with outstanding strength in rheumatic immunology
  • Professor of Tsinghua University School of Medicine
  • Clinical researcher of Center for Life Sciences jointly established by Tsinghua and Peking University

Rheumatoid Arthritis

Zhanguo LI, M.D.
  • Top-tier hospital with outstanding strength in rheumatic immunology
  • Director of Clinical Immunity Center and Department of Rheumatology and Immunology in Peking University